Hulk Hogan, wrestling icon, dies at 71 in Florida home
Investing.com - TD Cowen has reiterated its Buy rating and $115.00 price target on Boston Scientific (NYSE:BSX) ahead of the company’s second-quarter earnings report. The stock, currently trading near its 52-week high of $107.53, has delivered an impressive 16.03% return year-to-date. According to InvestingPro data, analyst targets range from $86.20 to $135.00, reflecting varied outlooks on this $154.51B healthcare equipment giant.
The medical device maker is scheduled to release its Q2 results before market open on Wednesday, July 23, with current guidance projecting reported revenue growth of 17.5-19.5% and organic growth of 13-15%, alongside adjusted EPS of $0.71-$0.73. The company has maintained strong momentum, with revenue growth of 19.36% over the last twelve months and an overall financial health score of "GREAT" according to InvestingPro analysis.
TD Cowen expects Boston Scientific to exceed Q2 estimates and modestly raise its 2025 organic sales growth guidance, while also increasing its full-year EPS guidance partly due to a more favorable tariff outlook.
Field checks throughout the quarter have shown continued strong demand for key products including Farapulse and Watchman, reinforcing confidence in the company’s growth trajectory despite macro headwinds.
The research firm also cited encouraging Q2 reports from industry peers, particularly Abbott Laboratories (NYSE:ABT), whose Medical (TASE:BLWV) Devices division exceeded 12% growth in the second quarter.
In other recent news, Boston Scientific has received FDA approval for a label expansion of its Watchman FLX and Watchman FLX Pro devices, now including post-ablation patients. This approval, supported by data from the OPTION trial, is expected to increase the indicated patient population by 1-2 million globally. Additionally, Boston Scientific’s FARAPULSE Pulsed Field Ablation (PFA) System has gained FDA approval to treat persistent atrial fibrillation (AF), expanding its use beyond paroxysmal AFib. The approval was backed by the ADVANTAGE AF trial, which showed favorable safety and efficacy outcomes. Analysts from BTIG and TD Cowen reiterated their Buy ratings on Boston Scientific, with price targets of $124.00 and $115.00, respectively. Piper Sandler maintained an Overweight rating, citing the strong performance of the Farapulse system, which generated approximately $1 billion in revenue during its first year of U.S. commercial launch. Meanwhile, Boston Scientific has decided to halt global sales of its Acurate neo2 and Acurate Prime TAVR systems, following discussions with regulators about additional requirements for approval. Despite this, Boston Scientific confirmed its guidance for reported and organic sales, as well as adjusted EPS, for the second quarter and full year of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.